Targeting of the protein interaction site between FAK and IGF-1R.

The interaction of focal adhesion kinase (FAK) and insulin-like growth factor-1 receptor (IGF-1R) plays an important role in cancer cell survival. Targeting this interaction with small molecule drugs could be a novel strategy in cancer therapy. By a series of pull-down assays using GST-tagged FAK fragments and His-tagged IGF-1R intracellular fragments, we showed that the FAK-NT2 (a.a. 127-243) domain directly interacts with the N-terminal part of the IGF-1R intracellular domain. Overexpressed FAK-NT2 domain was also shown to co-localize with IGF-1R in pancreatic cells. Computational modeling was used to predict the binding configuration of these two domains and to screen for small molecules binding to the interaction site. This strategy successfully identified a lead compound that disrupts FAK/IGF-1R interaction.

[1]  V. Golubovskaya,et al.  FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. , 2008, Carcinogenesis.

[2]  M. Iacocca,et al.  Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  H. Werner,et al.  Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways , 2008, Archives of Physiology and Biochemistry.

[4]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[5]  C. Livasy,et al.  Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  B. van de Water,et al.  Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.

[7]  Anil K Sood,et al.  Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. , 2004, The American journal of pathology.

[8]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[9]  Bob van de Water,et al.  Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.

[10]  M. Schaller,et al.  FAK regulates biological processes important for the pathogenesis of cancer , 2003, Cancer and Metastasis Reviews.

[11]  D. Schlaepfer,et al.  Control of motile and invasive cell phenotypes by focal adhesion kinase. , 2004, Biochimica et biophysica acta.

[12]  L. Kornberg,et al.  Focal adhesion kinase expression in oral cancers , 1998, Head & neck.

[13]  P. Nelson,et al.  An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer , 2007, Clinical Cancer Research.

[14]  D. Shalloway,et al.  Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation , 1992, Nature.

[15]  S. Hanks,et al.  Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases , 1995, Molecular and cellular biology.

[16]  B. Geiger,et al.  Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk. , 2001, Nature reviews. Molecular cell biology.

[17]  P. Karplus,et al.  Structure of the ERM Protein Moesin Reveals the FERM Domain Fold Masked by an Extended Actin Binding Tail Domain , 2000, Cell.

[18]  F. Peruzzi,et al.  The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.

[19]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[20]  David Cunningham,et al.  Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. , 2009, Recent patents on anti-cancer drug discovery.

[21]  J. Parsons,et al.  Focal adhesion kinase and associated proteins. , 1994, Current opinion in cell biology.

[22]  C. Livasy,et al.  Focal Adhesion Kinase Overexpression in Endometrial Neoplasia , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[23]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[24]  Beat Imhof,et al.  The inner lives of focal adhesions. , 2002, Trends in cell biology.

[25]  S. Brewster,et al.  Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer , 2005, Cancer Gene Therapy.

[26]  J. Ruidavets,et al.  Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. , 2004, Cancer research.

[27]  Xinming Cai,et al.  Structural Basis for the Autoinhibition of Focal Adhesion Kinase , 2007, Cell.

[28]  Kenneth M. Yamada,et al.  Cell interactions with three-dimensional matrices. , 2002, Current opinion in cell biology.

[29]  Kenneth M. Yamada,et al.  Transmembrane crosstalk between the extracellular matrix and the cytoskeleton , 2001, Nature Reviews Molecular Cell Biology.

[30]  L. T. Ten Eyck,et al.  Protein docking using continuum electrostatics and geometric fit. , 2001, Protein engineering.

[31]  J. Guan,et al.  Regulation of Focal Adhesion Kinase by Its Amino-Terminal Domain through an Autoinhibitory Interaction , 2003, Molecular and Cellular Biology.

[32]  H. Werner,et al.  Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways , 2008, Archives of physiology and biochemistry.

[33]  S. Hanks,et al.  Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. , 2003, Frontiers in bioscience : a journal and virtual library.

[34]  S. Stirdivant,et al.  Crystal Structure of the Apo, Unactivated Insulin-like Growth Factor-1 Receptor Kinase , 2002, The Journal of Biological Chemistry.

[35]  L. Kornberg.  Focal adhesion kinase and its potential involvement in tumor invasion and metastasis , 1998, Head & neck.

[36]  L. Bégin,et al.  Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma , 1996, International journal of cancer.

[37]  W. Cance,et al.  Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. , 1995, Cancer research.

[38]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[39]  A. Magis,et al.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. , 2008, Journal of medicinal chemistry.

[40]  J. Parsons,et al.  pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Baserga,et al.  IGF-I receptor signalling in transformation and differentiation , 2001, Molecular pathology : MP.

[42]  M. Eck,et al.  Crystal Structure of the FERM Domain of Focal Adhesion Kinase* , 2006, Journal of Biological Chemistry.

[43]  Xiaping He,et al.  Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma , 1999, Cancer.

[44]  Roberto D Lins,et al.  Prediction of HIV-1 integrase/viral DNA interactions in the catalytic domain by fast molecular docking. , 2004, Journal of medicinal chemistry.

[45]  S. Hanks,et al.  Signaling through focal adhesion kinase , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.